The global transfection technologies market size was estimated to be USD 2.85 billion in 2023 and is expected to reach at USD 7.08 billion by 2034 with a CAGR of 8.62% during the forecast period 2024-2034. Rising prevalence of cancer & various chronic lifestyle diseases, increasing technological advancements in cell research & therapeutic discovery, growing investments by government & private organizations for the development of large-scale transfection facilities, surge in research & development in the field of cell-based therapies, rising usage of transfection, and increasing launch of advanced transfection platforms by leading market players are some of the important elements driving the market's expansion.
Increasing launch of advanced transfection platforms by leading market players is predicted to boost the market growth during the forecast period. Transfection reagents play a crucial role in modern biotechnological processes. They are in high demand for efficiently transporting DNA, siRNA, oligos, and RNA into both adherent and suspension cells, including those that are challenging to transfect. As a result, there is an increasing demand for state-of-the-art transfection platforms, which is contributing to the market's growth. For instance, in August 2023, Polyplus part of Satorius, a leading upstream solutions provider for advanced biologic and cell and gene therapy production from research to commercial grade, is announcing the pre-order availability of FectoVIR®-LV transfection reagent for lentiviral vector (LV) production.
By method, reagent-based method was the highest revenue-grossing segment in the global transfection technologies market in 2023 owing to its affordability & the simpler techniques used during transfection, increasing demand of transfection reagents for the introduction of nucleic acid into eukaryotic cells either unpurified or purified, and growing launch of reagent-based transfection technologies. Additionally, instrument-based method is predicted to grow at fastest CAGR during the forecast period owing to a faster & more precise process, growing technological advancements, and rising adoption in various method includes electroporation, microinjection, biolistic technology, & laserfection, and increasing mergers & acquisitions within market players. For instance, in February 2022, Polypus, a company specializing in transaction reagents, has acquired e-Zyvec, a French-based firm offering DNA design and production services for customized DNA vectors. This acquisition is aimed at broadening their capabilities in the field of plasmid DNA vector engineering.
By technology, biochemical-based transfection was the highest revenue-grossing segment in the global transfection technologies market in 2023 owing to surge in research & development activities in gene therapy, rising focus on development of recombinant cell lines, and increasing technological advancements. Additionally, viral-vector-based transfection is predicted to grow at fastest CAGR during the forecast period owing to the viral vector's high precision in comparison to gene transfer because virus-mediated transfection uses a viral vector to carry DNA and RNA into cells and rising launch of innovative products. For instance, in September 2022, Polyplus, a prominent provider of upstream solutions for advanced biologics and cell and gene therapy production across research and commercial stages, is further expanding its mRNA support offerings. The company has introduced the in vivo-jetRNA+ transfection reagent, designed for in vivo delivery of mRNA utilizing a preformed liposome approach.
By application, therapeutic delivery was the highest revenue-grossing segment in the global transfection technologies market in 2023 owing to increasing demand for more scalable viral vectors for gene therapy and surge in technological advancements such as electroporation. Additionally, biomedical research is predicted to grow at fastest CAGR during the forecast period owing to the growing research & development activities, increasing launch of advanced products, and rising mergers & acquisitions within market players. For instance, in January 2023, The Binding Site Group, a well-known international supplier of specialist diagnostics, has been successfully acquired by Thermo Fisher Scientific Inc. This acquisition was carried out through an all-cash transaction valued at £2.3 billion, which is equivalent to $2.8 billion based on current exchange rates. The acquisition involved a shareholder group led by the European private equity firm Nordic Capital.
By end-user, pharmaceutical & biopharmaceutical was the highest revenue-grossing segment in the global transfection technologies market in 2023 owing to increasing focus on development of innovative vaccines and rising investment by leading market players, and surge in launch of advanced products. For instance, in May 2022, AGC Biologics has expanded its commercial-grade campus in Longmont, Colorado, to include viral vector suspension technology and increased capacity for the development and production of gene therapies. These new capabilities began becoming operational in the third quarter of 2022 and are enhancing the site's existing services for adherent viral vectors and cell therapies. Additionally, academic & research institutes is predicted to grow at fastest CAGR during the forecast period owing to the growing research & development activities in the area of stem cells & cellular therapies and rising funding for research by major market players.
North America region is anticipated for the highest revenue share during the forecast period owing to the surge in prevalence of chronic diseases such as cancer, rising use of viral vectors, increasing adoption of transfection technologies in cancer therapeutics, growing focus on viral vector manufacturing, surge in funding for research & development activities, and rising launch of innovative products. For instance, in February 2022, Mirus Bio, a prominent supplier of delivery solutions under Gamma Biosciences, has introduced the TransIT-VirusGEN SELECT Transfection Kits. These kits are tailored for the substantial production of viral vectors in the context of cell and gene therapy applications. Additionally, Europe region is predicted to grow at fastest CAGR during the forecast period owing to the increasing prevalence of cancer & infectious diseases, rising number of biotechnological companies & research institutes, growing demand for commercial reagents, and surge in funding by major market players. For instance, in January 2022, Cellino Biotech, an autonomous producer of cellular treatment solutions, secured $80 million in a Series A funding round. With the goal of expanding access to therapies based on stem cells, Cellino plans to establish the initial self-reliant human cell production facility by 2025.
Increasing launch of advanced transfection platforms by leading market players is predicted to boost the market growth during the forecast period. Transfection reagents play a crucial role in modern biotechnological processes. They are in high demand for efficiently transporting DNA, siRNA, oligos, and RNA into both adherent and suspension cells, including those that are challenging to transfect. As a result, there is an increasing demand for state-of-the-art transfection platforms, which is contributing to the market's growth. For instance, in August 2023, Polyplus part of Satorius, a leading upstream solutions provider for advanced biologic and cell and gene therapy production from research to commercial grade, is announcing the pre-order availability of FectoVIR®-LV transfection reagent for lentiviral vector (LV) production.
By method, reagent-based method was the highest revenue-grossing segment in the global transfection technologies market in 2023 owing to its affordability & the simpler techniques used during transfection, increasing demand of transfection reagents for the introduction of nucleic acid into eukaryotic cells either unpurified or purified, and growing launch of reagent-based transfection technologies. Additionally, instrument-based method is predicted to grow at fastest CAGR during the forecast period owing to a faster & more precise process, growing technological advancements, and rising adoption in various method includes electroporation, microinjection, biolistic technology, & laserfection, and increasing mergers & acquisitions within market players. For instance, in February 2022, Polypus, a company specializing in transaction reagents, has acquired e-Zyvec, a French-based firm offering DNA design and production services for customized DNA vectors. This acquisition is aimed at broadening their capabilities in the field of plasmid DNA vector engineering.
By technology, biochemical-based transfection was the highest revenue-grossing segment in the global transfection technologies market in 2023 owing to surge in research & development activities in gene therapy, rising focus on development of recombinant cell lines, and increasing technological advancements. Additionally, viral-vector-based transfection is predicted to grow at fastest CAGR during the forecast period owing to the viral vector's high precision in comparison to gene transfer because virus-mediated transfection uses a viral vector to carry DNA and RNA into cells and rising launch of innovative products. For instance, in September 2022, Polyplus, a prominent provider of upstream solutions for advanced biologics and cell and gene therapy production across research and commercial stages, is further expanding its mRNA support offerings. The company has introduced the in vivo-jetRNA+ transfection reagent, designed for in vivo delivery of mRNA utilizing a preformed liposome approach.
By application, therapeutic delivery was the highest revenue-grossing segment in the global transfection technologies market in 2023 owing to increasing demand for more scalable viral vectors for gene therapy and surge in technological advancements such as electroporation. Additionally, biomedical research is predicted to grow at fastest CAGR during the forecast period owing to the growing research & development activities, increasing launch of advanced products, and rising mergers & acquisitions within market players. For instance, in January 2023, The Binding Site Group, a well-known international supplier of specialist diagnostics, has been successfully acquired by Thermo Fisher Scientific Inc. This acquisition was carried out through an all-cash transaction valued at £2.3 billion, which is equivalent to $2.8 billion based on current exchange rates. The acquisition involved a shareholder group led by the European private equity firm Nordic Capital.
By end-user, pharmaceutical & biopharmaceutical was the highest revenue-grossing segment in the global transfection technologies market in 2023 owing to increasing focus on development of innovative vaccines and rising investment by leading market players, and surge in launch of advanced products. For instance, in May 2022, AGC Biologics has expanded its commercial-grade campus in Longmont, Colorado, to include viral vector suspension technology and increased capacity for the development and production of gene therapies. These new capabilities began becoming operational in the third quarter of 2022 and are enhancing the site's existing services for adherent viral vectors and cell therapies. Additionally, academic & research institutes is predicted to grow at fastest CAGR during the forecast period owing to the growing research & development activities in the area of stem cells & cellular therapies and rising funding for research by major market players.
North America region is anticipated for the highest revenue share during the forecast period owing to the surge in prevalence of chronic diseases such as cancer, rising use of viral vectors, increasing adoption of transfection technologies in cancer therapeutics, growing focus on viral vector manufacturing, surge in funding for research & development activities, and rising launch of innovative products. For instance, in February 2022, Mirus Bio, a prominent supplier of delivery solutions under Gamma Biosciences, has introduced the TransIT-VirusGEN SELECT Transfection Kits. These kits are tailored for the substantial production of viral vectors in the context of cell and gene therapy applications. Additionally, Europe region is predicted to grow at fastest CAGR during the forecast period owing to the increasing prevalence of cancer & infectious diseases, rising number of biotechnological companies & research institutes, growing demand for commercial reagents, and surge in funding by major market players. For instance, in January 2022, Cellino Biotech, an autonomous producer of cellular treatment solutions, secured $80 million in a Series A funding round. With the goal of expanding access to therapies based on stem cells, Cellino plans to establish the initial self-reliant human cell production facility by 2025.
Segmentation: Transfection Technologies Market Report 2022 - 2033
Transfection Technologies Market Analysis & Forecast by Method 2023 - 2034 (Revenue USD Bn)
- Instrument-Based Method
- Reagent- Based Method
- Others
Transfection Technologies Market Analysis & Forecast by Technology 2023 - 2034 (Revenue USD Bn)
- Biochemical-Based Transfection
- Viral-Vector-Based Transfection
- Physical Transfection
Transfection Technologies Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Therapeutic Delivery
- Protein Production
- Biomedical Research
- Stable Cell Line Generation
- Virus Production
- Protein Production
- Gene Silencing
- Stem Cell Reprogramming & Differentiation
- Others
Transfection Technologies Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Contract Research Organization
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
Transfection Technologies Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Transfection Technologies Market: Method Estimates & Trend Analysis
8. Transfection Technologies Market: Technology Estimates & Trend Analysis
9. Transfection Technologies Market: Application Estimates & Trend Analysis
10. Transfection Technologies Market: End-user Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Transfection Technologies Market
13. Europe Global Transfection Technologies Market
14. Asia Pacific Global Transfection Technologies Market
15. Latin America Global Transfection Technologies Market
16. MEA Global Transfection Technologies Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Qiagen NV
- Bio-Rad Laboratories Inc.
- SignaGen Laboratories
- Promega Corporation
- Mirus Bio
- Thermo Fisher Scientific
- Sigma Aldrich
- Merck KGaA
- Lonza Group
- Altogen Biosystems
- Maxcyte
- Polyplus-transfection SA
- Roche
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | October 2023 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 2.85 Billion |
| Forecasted Market Value ( USD | $ 7.08 Billion |
| Compound Annual Growth Rate | 8.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 13 |
